CLYM NASDAQ
Climb Bio, Inc.
1W: -6.2%
1M: -27.3%
3M: -17.6%
YTD: +191.7%
1Y: +455.3%
$10.94
-0.13 (-1.17%)
Weekly Expected Move ±8.9%
$9
$10
$11
$12
$13
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2024-06-27
Earliest Filing
2025-12-11
Latest Filing
supplier: 5
partner: 2
investor: 1
target: 1
Counterparties (Filed by CLYM)
9 relationshipsCompanies named in CLYM's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| RA Capital Management, L.P. | — | investor | Entered into an exchange agreement to receive pre-funded warrants in exchange for common stock. | 2025-12-11 | View |
| Oppenheimer & Co. Inc. | OPY | partner | Acted as sales agent for the Company's equity distribution agreement. | 2025-03-25 | View |
| Beijing Mabworks Biotech Co., Ltd. | — | partner | Climb Bio entered into a technology transfer and exclusive license agreement for MIL116 antibodies outside of China. | 2025-01-10 | View |
| Tenet Medicines, Inc. | — | target | Target company acquired by Eliem Therapeutics, Inc. via merger | 2024-06-27 | View |
| Acelyrin, Inc. | — | supplier | Counterparty in asset purchase agreement for TNT119 assets and licenses | 2024-06-27 | View |
| WH2, LLC | — | supplier | Counterparty in asset purchase agreement with Tenet Medicines, Inc. | 2024-06-27 | View |
| Cancer Research Technology Limited | — | supplier | Licensor of TNT119 intellectual property rights to Tenet Medicines, Inc. | 2024-06-27 | View |
| ProBioGen AG | — | supplier | Licensor and service provider for cell line development and manufacturing | 2024-06-27 | View |
| ValenzaBio, Inc. | — | supplier | Original counterparty to ProBioGen Agreement assigned to Tenet Medicines, Inc. | 2024-06-27 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-03 | Regulation FD; Exhibits | View | |
| 2026-08-14 | Other Events | View | |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-07-01 | Officer/Director Change | View | |
| 2026-06-12 | Material Agreement; Other Events; Exhibits | Agreement | View |
| 2026-06-11 | Other Events | View | |
| 2026-06-08 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-06-05 | Other Events | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-05-05 | Regulation FD; Exhibits | View | |
| 2026-04-28 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-04-03 | Officer/Director Change | View | |
| 2026-03-05 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-08 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-12-31 | Other Events; Financial Statements and Exhibits | View | |
| 2025-12-11 | Entry into Material Definitive Agreement; Unregistered Sales of Equity Securities; Financial Stateme | Agreement | View |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-17 | Other Events | View | |
| 2025-10-01 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2025-09-29 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR